HIPK2 downregulates vimentin and inhibits breast cancer cell invasion

Cancer Biology and Therapy

Volumn 13, Issue 4, 2012, Pages 198-205

  Nodale, Cristina ^a   Sheffer, Michal ^b   Jacob Hirsch, Jasmine ^c,d   Folgiero, Valentina ^a   Falcioni, Rita ^a   Aiello, Aurora ^a,e   Garufi, Alessia ^a   Rechavi, Gideon ^c,d   Givol, David ^b   D'Orazi, Gabriella ^a,f  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

Author keywords

Breast cancer; HIPK2; Hypoxia; Invasion; Tumor suppressor; Vimentin

Indexed keywords

DOXORUBICIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; VIMENTIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE REPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MESENCHYME CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION;

APOPTOSIS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FEMALE; HUMANS; NEOPLASM INVASIVENESS; PROTEIN-SERINE-THREONINE KINASES; TRANSFECTION; VIMENTIN;

EID: 84857488842     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.4.18694     Document Type: Article

References (46)

1. Calzado MA, Renner F, Roscic A, Schmitz ML. HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 2007; 6:139-43; PMID:17245128; http://dx.doi.org/10.4161/cc.6.2.3788
2. Rinaldo C, Prodosmo A, Siepi F, Soddu S. HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol 2007; 85:411-8; PMID:17713576; http://dx.doi.org/10.1139/O07-071
3. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nat Cell Biol 2002; 4:11-9; PMID:11780126; http://dx.doi.org/10.1038/ncb714
4. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 2003; 115:177-86; PMID:14567915; http://dx.doi.org/10.1016/S0092-8674(03)00802-X
5. Hofmann TG, Stollberg N, Schmitz ML, Will H. HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res 2003; 63:8271-7; PMID:14678985
6. Doxakis E, Huang EJ, Davies AM. Homeodomain-interacting protein-2 regulates apoptosis in developing sensory and sympathetic neurons. Curr Biol 2004; 14:1761-5; PMID:15458648; http://dx.doi.org/10.1016/j.cub.2004.09.050
7. Nardinocchi L, Puca R, Sacchi A, D'Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 2009; 8:1-9; PMID:19128456; http://dx.doi.org/10.1186/1476-4598-8-1
8. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS ONE 2009; 4:e6819; PMID:19714248; http://dx.doi.org/10.1371/journal.pone.0006819
9. Steinert PM, Roop DR. Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 1988; 57:593-625; PMID:3052284; http://dx.doi.org/ 10.1146/annurev.bi.57.070188.003113
10. Ivaska J. Vimentin: Central hub in EMT induction? Small GTPases 2011; 2:51-3; PMID:21686283; http:// dx.doi.org/10.4161/sgtp.2.1.15114
11. Thiery JP. Epithelial-mesenchimal transition in tumor progression. Nat Rev Cancer 2002; 2:442-54; PMID: 12189386; http://dx.doi.org/10.1038/nrc822
12. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004; 10:4125-33; PMID:15217949; http://dx.doi.org/ 10.1158/1078-0432.CCR-0578-03
13. Zhao Y, Yan Q, Long X, Chen X, Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 2008; 26:571-7; PMID: 18464297; http://dx.doi.org/10.1002/cbf.1478
14. Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valverius E, Clark R, et al. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogenes-transformed mammary epithelial cells. Cancer Res 1989; 49:4258-63; PMID:2472876
15. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, et al. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 1992; 52:5190-7; PMID: 1382837
16. Gilles C, Polette M, Piette J, Delvigne AC, Thompson EW, Foidart JM, et al. Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J Pathol 1996; 180:175-80; PMID:8976877; http://dx.doi.org/10.1002/(SICI)1096-9896(199610) 180:2〈175::AID- PATH630〉3.0.CO;2-G
17. Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 1990; 136:219-27; PMID:2153347
18. Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, et al. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res 1999; 5:2698-703; PMID:10537332
19. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi J-P, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by Slug and oncogenes H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011; 30:1436-8; PMID:21057535; http://dx.doi.org/ 10.1038/onc.2010.509
20. Satelli A, Li S. Vimentin in cancer and its potential as molecular target for cancer therapy. Cell Mol Life Sci 2011; 68:3033-46; PMID:21637948; http://dx.doi. org/10.1007/s00018-011-0735-1
21. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994; 31:325-35; PMID:7881109; http://dx.doi.org/ 10.1007/BF00666165
22. Janda E, Nevolo M, Lehmann K, Downward J, Beung H, Grieco M. Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene 2006; 25:7117-30; PMID: 16751808; http://dx.doi.org/10. 1038/sj.onc.1209701
23. Fabre-Guillevin E, Malo M, Cartier-Michaud A, Peinado H, Moreno-Bueno G, Vallee B, et al. PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. Breast Cancer Res 2008; 10:R100; PMID: 19055748; http://dx.doi.org/ 10.1186/bcr2203
24. Gilles C, Polette Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 2003; 63:2658-64; PMID:12750294
25. Wu Y, Zhang X, Salmon M, Zehner ZE. The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells 2007; 12:905-18; PMID:17663720; http://dx.doi.org/10.1111/j.1365-2443.2007. 01104.x
26. Puca R, Nardinocchi L, Givol D, D'Orazi G. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in cancer cells. Oncogene 2010; 29:4378-87; PMID:20514025; http://dx.doi.org/10.1038/onc.2010.183
27. Smith L, Watson MB, O'Kane SL, Drew PL, Lind MJ, Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther 2006; 5:2115-20; PMID:16928833; http://dx.doi.org/10.1158/1535-7163.MCT-06-0190
28. Yang M-H, Wu M-Z, Chiou S-H, Chen P-M, Chang S-Y, Liu C-J, et al. Direct regulation of TWIST by HIF-1a promotes metastasis. Nat Cell Biol 2008; 10:295-305; PMID:18297062; http://dx.doi.org/10.1038/ncb1691
29. Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, Michiels C, et al. Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta 2009; 1793:368-77; PMID:19046997; http://dx.doi.org/10.1016/j.bbamcr.2008.10.013
30. Wang GL, Jiang H, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92:5510-4; PMID:7539918; http://dx.doi.org/10.1073/pnas. 92.12.5510
31. Puca R, Nardinocchi L, D'Orazi G. Regulation of vascular endothelial growth factor expression by homeodomain-interacting protein kinase-2. J Exp Clin Cancer Res 2008; 27:22; PMID:18644116; http://dx.doi.org/10.1186/1756-9966-27- 22
32. Choi CY, Kim YH, Kwon HJ, Kim Y. The Homeodomain protein NK-3 recruits Groucho and histone deacetylase complex to repress transcription. J Biol Chem 1999; 274:33194-7; PMID:10559189; http://dx.doi.org/10.1074/jbc.274.47.33194
33. Hendrix MJ, Seftor EA, Seftor RE, Trevor KT. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behaviour. Am J Pathol 1997; 150:483-95; PMID:9033265
34. Gilles C, Polette M, Zahn JM, Tournier JM, Volders L, Foidart JM, et al. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 1999; 112:4615-25; PMID:10574710
35. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003; 63:2306-11; PMID:12727854
36. McInroy L, Maatta A. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun 2007; 360: 109-14; PMID:17585878; http://dx.doi.org/10.1016/j.bbrc.2007.06.036
37. Calzado MA, de la Vega L, Moller A, Bowtell DD, Schmitz ML. An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response. Nat Cell Biol 2009; 11:85-91; PMID:19043406; http://dx.doi.org/10.1038/ncb1816
38. Michieli P. Hypoxia, angiogenesis and cancer therapy. Cell Cycle 2009; 8:3291; PMID:19770588; http://dx.doi.org/10.4161/cc.8.20.9741
39. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625-34; PMID:19946328; http://dx.doi.org/10.1038/onc.2009.441
40. Nardinocchi L, Puca R, Givol D, D'Orazi G. HIPK2: A therapeutical target to be (re)activated for tumor suppression. Role in p53 activation and HIF-1a inhibition. Cell Cycle 2010; 9:1-2; PMID:20016263; http://dx.doi.org/10.4161/cc. 9.7.11125
41. Puca R, Nardinocchi L, Pistritto G, D'Orazi G. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 2008; 109:403-10; PMID:18395248; http://dx.doi.org/10.1016/j. ygyno.2008.02.018
42. Bon G, Di Carlo S, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, et al. Negative regulation of b4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 inpmairs tumor progression. Cancer Res 2009; 69:5978-86; PMID:19567674; http://dx.doi.org/10.1158/0008-5472.CAN-09-0244
43. Ballman KV, Grill DE, Oberg AL, Therneau TM. Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics 2004; 20:2778-86; PMID:15166021; http://dx.doi.org/10.1093/bioinformatics/bth327
44. Zeisel A, Amir A, Kostler WJ, Domany E. Intensity dependent estimation of noise in microarrays improves detection of differentially expressed genes. BMC Bioinformatics 2010; 11:400; PMID:20663218; http://dx.doi.org/10.1186/1471-2105- 11-400
45. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 2004; 293: 311-20; PMID:14729469; http://dx.doi.org/10.1016/j.yexcr.2003.09.032
46. Falk W, Goodwin RH, Jr., Leonard EJ. A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte results. J Immunol Methods 1980; 33:201-12; PMID:6966301